| Drug Name |
Tocilizumab |
| Drug ID |
BADD_D02234 |
| Description |
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.[L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies.[A193281] It is currently being investigated to treat severely ill patients with COVID-19.[A193278,L12837,L12843]
Tocilizumab was granted FDA approval on 8 January 2010.[L12789] |
| Indications and Usage |
Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older. |
| Marketing Status |
Prescription |
| ATC Code |
L04AC07 |
| DrugBank ID |
DB06273
|
| KEGG ID |
D02596
|
| MeSH ID |
C502936
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D08HPZ
|
| NDC Product Code |
50242-135; 71124-0019; 50242-157; 50242-138; 50242-136; 50242-137; 50242-158; 50242-139; 50242-143; 50242-141 |
| Synonyms |
tocilizumab | atlizumab | monoclonal antibody, MRA | BAT-1806 | BAT1806 | MSB11456 | MSB-11456 | RG-1569 | R-1569 | RO-4877533 | Actemra | Roactemra | RHPM-1 |
